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ABSTRACT 
Introduction: studying the way of how to improve tissue tolerance to ischemia is an actual problem of 
pharmacology. Up to now, the treatment of ischemic retinal conditions was done by use of angioprotectors, 
antioxidants, fibrinolytics, anticoagulants and others. Due to the instability and short-term effects after using these 
drugs and physiotherapy treatments is necessary to seek out a more effective way to improve blood circulation and 
increase resistance to ischemic retinal tissue. 
Research tasks: to increase the effectiveness of pharmacological correction of retinal ischemia-reperfusion by 
using agonist of imidazoline receptors type I, II, 3-(1H-benzimidazol-2-il)-1,2,2-trimethyl cyclopentancarbonic 
acid. 
Methods: to investigate the fundus of experimental animals a direct ophthalmoscopy was used. To zoom a lens 
Osher MaxField 78D model OI-78M has been used. Electroretinography was performed at once after the 
ophthalmoscopy. To assess the degree of functional damage to the retina we evaluated the ratio of amplitudes of 
a- and b- waves - the coefficient b/a. For all data, the descriptive statistics were used, and data are checked for 
normal distribution. Distribution type was determined by using the criterion of Shapiro-Wilk. Between-group 
differences were analyzed by parametric (t-Student criterion) or non-parametric (Mann-Whitney test) methods, 
depending on the type of distribution. Differences were determined at 0.05 significance level. 
Results: the protective effect of agonist of imidazoline receptors type I, II, 3-(1H-benzimidazol-2-il)-1,2,2-
trimethyl cyclopentancarbonic acid, in doses 10 mg/kg, 50 mg/kg on the retinal ischemia-reperfusion model on 
Wistar rats was studied. In the experiment it was found that the 3-(1H-benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid in a dose 50 mg/kg prevents the development of neuronal damage in the retina caused 
by intraocular pressure increase to 110 mm Hg within 30 min by applying the mechanical pressure to the anterior 
chamber of the eye to a greater extent than in a dose 10 mg/kg. The detected protective effects were confirmed by 
the results of ophthalmoscopy and electroretinography after 72 hours of reperfusion. 
Conclusion: results of ocular fundus studies revealed the most pronounced protective effects of 3-(1H-
benzimidazol-2-il)-1,2,2-trimethyl cyclopentancarbonic acid in a dose 50 mg/kg on the model of retinal ischemia-
reperfusion in Wistar rats, which is reflected in the restoration of the optic disc. Correction of retinal ischemia-
reperfusion by 3-(1H-benzimidazol-2-il)-1,2,2-trimethyl cyclopentancarbonic acid in a dose 50 mg/kg leads to 
higher values of the coefficient b/a of electroretinography after 72 hours of reperfusion compared to the group 
with pathology correction by the same drug in a dose 10 mg/kg, which indicates the restoration of the 
electrophysiological state of the retina. 
 
Key words: 3-(1H-benzimidazol-2-il)-1,2,2-trimethyl cyclopentancarbonic acid, retinal ischemia-reperfusion, 
ophthalmoscopy, electroretinography. 
 
INTRODUCTION 
Local circulatory disorders in the branches of 
retinal artery are observed in diabetic 
retinopathy, hypertensive retinopathy, 
degenerative diseases of the retina, optic nerve 
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atrophy vascular origin, traumatic eye injury, 
ischemic neuropathy [1, 2, 3]. The search for 
innovative molecules [4, 5] is an important task 
of pharmacology. Moreover, their study should 
be carried out on pharmacological targets [6, 7], 
in vivo models [8, 9].  
Studying the way of how to improve tissue 
tolerance to ischemia is an actual problem of 
modern experimental and clinical 
pharmacology. Up to now, the treatment of 
ischemic retinal conditions was done by use of 
angioprotectors, antioxidants, fibrinolytics, 
anticoagulants and others. As the authors note, 
due to the instability and short-term effects after 
using these drugs and physiotherapy treatments 
is necessary to seek out a more effective way to 
improve blood circulation and increase 
resistance to ischemic retinal tissue having a 
specific orientation [10]. Thus, an important task 
is to find new, specific and highly effective 
means for correcting of retinal ischemia. 
Imidazoline receptors are located on the 
membranes of mitochondria and are actively 
associated with antioxidant and monoamine 
oxidase enzyme systems. In this regard, the 
correction of mitochondrial activity can largely 
level out ischemic and reperfusion damage to 
the retina. 
In connection with the foregoing, it should be 
noted the relevance of the study of 3-(1H-
benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid as a protective agent 
on the model of retinal ischemia-reperfusion. 
 
MATERIALS AND METHODS 
Experiments were carried out on Wistar rats 
weighing 250 ± 25 g. Ethical principles of 
handling laboratory animals are observed in 
accordance with the «European Convention for 
the Protection of Vertebral Animals Used for 
Experimental and Other Scientific Purposes. 
CETS No. 123». Manipulations on rats were 
carried out under general anesthesia with 
intraperitoneal (i/p) administration of an 
aqueous solution of chloral hydrate in a dose 
300 mg/kg of rat weight. 
3-(1H-benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid, 10 mg/kg,  50 mg/kg 
was administered intragastrically (i/g) once 1 h 
before ischemia-reperfusion modeling. 
Ischemia-reperfusion injury of the retina was 
simulated under anesthesia by applying 
mechanical pressure (110 mm Hg) to the 
anterior eye chamber within 30 min [10]. 
To study the fundus in experimental animals, 
direct ophthalmoscopy was used after 72 h of 
reperfusion (Bx a Neitz ophthalmoscope, Japan). 
To expand the pupil, eye drops Irifrin 2.5% were 
used. The ophthalmoscope was approached to 
the rat`s eye and sent a beam of light at a 
distance of 0.5-2 cm to obtain a clear picture of 
the fundus. To increase the image, the lens 
Osher MaxField 78D model OI-78M was used 
[11]. 
Electroretinography (ERG) was performed 
immediately after ophthalmoscopy. For this 
purpose, the animals were kept in the dark 
within 30 min [12], then anesthetized and fixed 
on a table. The corneal silver electrode was 
placed on the cornea, the reference needle 
electrode EL452 was placed subcutaneously 
(s/c) in the skull region, the ground needle 
electrode EL450 was placed in the base of the 
tail. A stroboscope with a flash of white light, 
connected to the stimulator STM200 by Biopac 
System, Inc. (USA) were placed behind the 
animal back, the ERG was recorded in response 
to a single stimulation. The induced 
biopotentials were amplified, averaged and 
presented graphically on the screen with help of 
Biopac-systems MP-150 and program 
AcqKnowledge 4.2 (USA). To evaluate the 
degree of development of functional retinal 
damage, the ratio of the amplitudes of the b- and 
a-waves of the ERG, the coefficient b/a, was 
estimated [13]. From the 10 values obtained in 
each group, the average was output, which was 
recorded in the protocol. 
For all data the descriptive statistics were 
applied: the data were checked for the 
normality of the distribution. The type of 
distribution was determined by the Shapiro-
Wilk criterion. In the case of a normal 
distribution, the average value (M) and the 
standard error of the mean (m) were 
calculated. In cases of abnormal distribution, 
the median (Me) and the quarterly range 
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(QR) were calculated. Intergroup differences 
were analyzed by parametric (Student's t-test) 
or nonparametric (Mann-Whitney test) 
methods, depending on the distribution type. 
Differences were determined at 0.05 
significance level. Statistical analysis is 
performed using the software Statistica 10.0. 
We used our own modification of the model of 
retinal ischemia-reperfusion, in which the 
increase in intraocular pressure (IOP) is due to 
mechanical pressure (110 mm Hg) on the 
anterior chamber of the eye [13]. 
The experiment included 4 groups, 10 rats in 
each group: the first group - a group of intact 
animals; the second - a group with retinal 
ischemia-reperfusion (control); the third - with 
the correction of pathology by 3-(1H-
benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid in a dose 10 mg/kg; 
the fourth - with the correction by 3-(1H-
benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid in a dose 50 mg/kg. 
 
RESULTS AND DISCUSSION 
In accordance with the study protocol, after an 
IOP increase after 72 h of reperfusion anesthesia 
of animals was performed. Further, an 
ophthalmoscopy and assessment of the 
electrophysiological retinal state were 
performed. 
Example of ophthalmoscopy on intact animal is 
shown in fig. 1. 
 
Figure 1. Example of ophthalmoscopy on intact 
Wistar rat.  
 
Optic disc is circular or oval shape and stands 
out from the fundus in pink. The boundaries of 
disc are clear. It lies in the plane of the retina. 
From the middle of the disc exit the central 
vessels of the retina. Retinal blood vessels don`t 
have anastomoses. The veins and arteries are 
straightforward, caliber is uniform, not crimped. 
The general background is pink. Example of 
ophthalmoscopy on Wistar rat with modeling of 
retinal ischemia after 72 h of reperfusion is 
shown in fig. 2. 
 
Figure 2. Example of ophthalmoscopy on Wistar rat 
with modeling of retinal ischemia-reperfusion.  
 
Optic disc is edematous, edema extends to the 
retina. Blurring boundaries of disc. Viens are 
congested. Arteries are narrowed. Vessel caliber 
is uneven. Retina is palely (ischemic). Symptom 
Salus-Hun I (arrow + S I).  
Example of ophthalmoscopy in the group with 
correction by 3-(1H-benzimidazol-2-il)-1,2,2-
trimethyl cyclopentancarbonic acid in a dose 10 
mg/kg after 72 h of reperfusion is shown in fig. 
3. 
 
Figure 3. Example of ophthalmoscopy in the group 
with correction of retinal ischemia-reperfusion by 3-
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(1H-benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid in a dose 10 mg/kg.  
Optic disc is circular or oval shape and stands 
out from the fundus in pale - pink. The 
boundaries of disc are clear. It lies in the plane 
of retina. Viens are congested. Arteries are 
narrowed. Vessel caliber is uneven. Retina is 
palely (ischemic). Symptom Salus-Hun I (arrow 
+ S I). In the group with correction by 3-(1H-
benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid in a dose 50 mg/kg, 
the following pattern was observed: optic disc is 
round, pink, lies in the plane of the retina, the 
boundaries are clear. The veins and arteries are 
straight, the caliber is uniform, there is no crimp. 
The general background is pink. The picture of 
the fundus is close to normal. 
The results of evaluation of electrophysiological 
retinal function after 72 h of reperfusion in 
experimental groups are presented in tab. 1. 
Table 1: Results of electroretinography after 72 h of 
reperfusion (M ± m; n = 10), r.u. 
Experimental groups b/a 
Intact 2.5 ± 0.10 у 
Control 1.2 ± 0.04 * 
Correction by 3-(1H-benzimidazol-2-
il)-1,2,2-trimethyl cyclopentancarbonic 
acid, 10 mg/kg 
2.0 ± 0.15 у 
Correction by 3-(1H-benzimidazol-2-
il)-1,2,2-trimethyl cyclopentancarbonic 
acid, 50 mg/kg 
2.4 ± 0.10 у   
 
Comment: * - p<0.05 compared with the group 
of intact animals, у - р<0.05 compared with the 
control group 
Thus, the results of fundus studies and ERG in 
experimental groups revealed pronounced 
protective properties of 3-(1H-benzimidazol-2-
il)-1,2,2-trimethyl cyclopentancarbonic acid in a 
dose 50 mg/kg, exceeding its effect in a dose 10 
mg/kg, consisting in a reduction in the 
development of neuronal damage in the retina 
on the model of retinal ischemia-reperfusion, 
which were noted in the control group; an 
increase in the coefficient b/a in the groups with 
the correction of pathology, which is caused by 
the restoration of the positive wave b on the 
ERG and indicates the preservation of the 
electrophysiological function of the retina. 
Through the stimulation of І1 and І2 imidazoline 
receptors, 3-(1H-benzimidazol-2-il)-1,2,2-
trimethyl cyclopentancarbonic acid manifests 
antioxidant, antiatherogenic, reparative, 
cerebroprotective effects, etc. By means of 
cerebroprotective, nootropic activity, it prevents 
the development of severe consequences of 
acute cerebral circulation impairment according 
to the ischemic type, restores all phases of 
memory, contributes to the preservation of the 
histo- structure of the brain in conditions of 
cerebral ischemia of different genesis. 
The search of new methods of retinoprotection 
for possible reduction of the damaging effect of 
ischemia, formed in various systemic diseases, 
is an urgent task of pharmacology and 
ophthalmology [10]. Segment of drugs for the 
treatment of vascular and neuronal diseases of 
the eye such as complication from hypertension, 
diabetes, and others, is expedient to expand due 
to an increase in morbidity and lack of funds for 
targeted correction of ischemic lesions of the 
eye vessels. 
In connection with the foregoing, the study of 
the protective properties of the 3-(1H-
benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid on the model of retinal 
ischemia-reperfusion in the experiment was 
topical. 
Proceeding from the fact that the data of 
electrophysiological studies are often of decisive 
importance in the early and differential 
diagnosis of retinal disorders [14], a complex 
analysis including ophthalmoscopic, 
electroretinographic, microcirculatory studies is 
needed to study the correction of functional 
changes in retina. 
 
CONCLUSION 
Results of ocular fundus studies revealed the 
most pronounced protective effects of 3-(1H-
benzimidazol-2-il)-1,2,2-trimethyl cyclopentan 
carbonic acid in a dose 50 mg/kg on the model 
of retinal ischemia-reperfusion in Wistar rats, 
which is reflected in the restoration of the optic 
disc. Correction of retinal ischemia-reperfusion 
by 3-(1H-benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentan carbonic acid in a dose 50 mg/kg 
leads to higher values of the coefficient b/a of 
electroretinography after 72 hours of reperfusion 
compared to the group with pathology 
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correction by the same drug in a dose 10 mg/kg, 
which indicates the restoration of the 
electrophysiological state of the retina. 
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